Topical imiquimod treatment of residual or recurrent cervical intraepithelial neoplasia lesions (TOPIC-2): A randomised controlled trial.

ABSTRACT:

Objective

To investigate the efficacy of imiquimod in women with residual or recurrent cervical intraepithelial neoplasia (rrCIN), compared with large loop excision of the transformation zone (LLETZ).

Design

Randomised controlled non-inferiority trial.

Setting

One academic and one regional hospital in the Netherlands.

Population

Thirty-five women with rrCIN were included in the study between May 2016 and May 2021.

Methods

Women were randomised to receive treatment with 5% imiquimod cream (12.5 mg) intravaginally (three times a week for a duration of 16 weeks) or a LLETZ procedure (standard treatment).

Main outcome measures

The primary outcome was reduction to normal cytology at 6 months after starting treatment. Secondary outcomes were clearance o

SUBMITTER: van de Sande AJM 

PROVIDER: S-EPMC12137755 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature